Publications by authors named "Anika Brunegraf"
Article Synopsis
- The study focuses on improving bone marrow (BM) dosimetry for patients receiving Lu-177 therapies for prostate cancer and neuroendocrine tumors through a hybrid protocol (HP).
- This new method combines multiple abdominal SPECT scans with a single whole-body planar (WB-P) imaging session, aiming to provide accurate dosimetry while being more efficient and patient-friendly.
- Results show the HP yields BM absorbed doses that are comparable to the traditional reference protocol (RP), with only slight deviations, demonstrating its effectiveness for both therapy types.
Background: PET ligands targeting the translocator protein (TSPO) represent promising tools to visualise neuroinflammation. Here, we analysed parameters obtained in dynamic and static PET images using the novel TSPO ligand [F]GE-180 in patients with relapsing remitting multiple sclerosis (RRMS) and an approach for semi-quantitative assessment of this disease in clinical routine. Seventeen dynamic [F]GE-180 PET scans of RRMS patients were evaluated (90 min).
View Article and Find Full Text PDFPurpose: Dosimetry is critical to achieve the optimal therapeutic effect of radioligand therapy (RLT) with limited side effects. Our aim was to perform image-based absorbed dose calculation for the new PSMA ligand (177)Lu-DKFZ-PSMA-617 in support of its use for the treatment of metastatic prostate cancer.
Methods: Whole-body planar images and SPECT/CT images of the abdomen were acquired in five patients (mean age 68 years) for during two treatment cycles at approximately 1, 24, 48 and 72 h after administration of 3.